ArticleDrug design, development and therapy2025
Oxysophocarpine Inhibits Apoptosis of Lung Epithelial Cells to Alleviate Acute Lung Injury via KIT/PI3K Signaling Pathway.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Acute lung injury (ALI) is an acute, diffuse, inflammatory lung injury caused by many factors. Oxysophocarpine (OSC), a quinoline alkaloid sourced from traditional Chinese herbs Methods: The levels of TNF-α, IL-6, and IL-1β in bronchoalveolar lavage fluid (BALF) were measured with an enzyme-linked immunosorbent assay (ELISA). Lung tissue changes were examined through hematoxylin and eosin (HE) staining. Lung cell apoptosis was analyzed using the terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay. Flow cytometry was utilized to detect neutrophil aggregation. Further, the network pharmacology and molecular docking was employed to predict the mechanisms. Key pathways and targets of OSC were confirmed using methods like immunohistochemistry (IHC), immunofluorescence (IF), real-time quantitative PCR (RT-qPCR), and Western blotting (WB). Results: In vivo, OSC treatment significantly inhibited diffuse alveolar injury and interstitial edema compared to the LPS-induced model mice, reduced neutrophil infiltration, and lowered lung epithelial cell apoptosis. In vitro, OSC pretreatment enhanced lung epithelial cell viability and decreased LPS-induced apoptosis. Network pharmacology analysis suggested that OSC mainly targeted key proteins in the PI3K/AKT and apoptosis signaling pathways, such as KIT, PIK3CA, and Bcl-2. Molecular docking confirmed that OSC binds strongly to these targets. Further, PCR, WB, IF, and IHC assay demonstrated that OSC pretreatment elevated PI3K, KIT, and Bcl-2 expressions in BEAS-2B lung epithelial cells and lung tissues. Conclusion: OSC reduced inflammatory cytokine production, neutrophil aggregation, and lung epithelial cell apoptosis via regulating the KIT/PI3K signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.